Literature DB >> 17953669

Regulation of A(2A) adenosine receptor expression and functioning following permanent focal ischemia in rat brain.

Maria L Trincavelli1, Alessia Melani, Sara Guidi, Serena Cuboni, Sara Cipriani, Felicita Pedata, Claudia Martini.   

Abstract

Ischemia, through modulation of adenosine receptors (ARs), may influence adenosine-mediated-cellular responses. In the present study, we investigated the modulation of rat A(2A) receptor expression and functioning, in rat cerebral cortex and striatum, following in vivo focal ischemia (24 h). In cortex, middle cerebral artery occlusion did not induce any alterations in A(2A) receptor binding and functioning. On the contrary, in striatum, a significant decrease in A(2A) ligand affinity, associated with an increase in receptor density, were detected. In striatum, ischemia also induced a significant reduction both in G protein pool and in A(2A) receptor-G protein coupling. On the contrary, A(2A) receptor functional responsiveness, measured as stimulation of adenylyl cyclise, was not affected by ischemia, suggesting receptor up-regulation may represent a compensatory mechanism to maintain receptor functioning during cerebral damage. Immunohistochemical study showed that following 24 h middle cerebral artery occlusion, A(2A) ARs were definitely expressed both on neurons and activated microglia in ischemic striatum and cortex, but were not detected on astrocytes. In the non-ischemic hemisphere and in sham-operated rats A(2A) ARs were barely detected. Modifications of ARs may play a significant role in determining adenosine effects during ischemia and therefore should be taken into account when evaluating time-dependent protective effects of specific A(2A) active compounds.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17953669     DOI: 10.1111/j.1471-4159.2007.04990.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  16 in total

1.  A(₂A) adenosine receptor (A(₂A)AR) as a therapeutic target in diabetic retinopathy.

Authors:  Ahmed S Ibrahim; Mamdouh M El-Shishtawy; Wenbo Zhang; Ruth B Caldwell; Gregory I Liou
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease.

Authors:  Patricia K Sonsalla; Lai-Yoong Wong; Suzan L Harris; Jason R Richardson; Ida Khobahy; Wenhao Li; Bharathi S Gadad; Dwight C German
Journal:  Exp Neurol       Date:  2012-01-28       Impact factor: 5.330

Review 3.  Neurobiology of microglial action in CNS injuries: receptor-mediated signaling mechanisms and functional roles.

Authors:  Xiaoming Hu; Anthony K F Liou; Rehana K Leak; Mingyue Xu; Chengrui An; Jun Suenaga; Yejie Shi; Yanqin Gao; Ping Zheng; Jun Chen
Journal:  Prog Neurobiol       Date:  2014-06-09       Impact factor: 11.685

4.  Variants of the adenosine A(2A) receptor gene are protective against proliferative diabetic retinopathy in patients with type 1 diabetes.

Authors:  Bashira A Charles; Yvette P Conley; Guanjie Chen; Rachel G Miller; Janice S Dorman; Michael B Gorin; Robert E Ferrell; Susan M Sereika; Charles N Rotimi; Trevor J Orchard
Journal:  Ophthalmic Res       Date:  2010-11-19       Impact factor: 2.892

5.  Time-course of protection by the selective A2A receptor antagonist SCH58261 after transient focal cerebral ischemia.

Authors:  Alessia Melani; Ilaria Dettori; Francesca Corti; Lucrezia Cellai; Felicita Pedata
Journal:  Neurol Sci       Date:  2015-03-25       Impact factor: 3.307

6.  Receptor crosstalk: haloperidol treatment enhances A(2A) adenosine receptor functioning in a transfected cell model.

Authors:  Maria Letizia Trincavelli; Serena Cuboni; Mario Catena Dell'osso; Roberto Maggio; Karl-Norbert Klotz; Francesca Novi; Anna Panighini; Simona Daniele; Claudia Martini
Journal:  Purinergic Signal       Date:  2010-10-12       Impact factor: 3.765

7.  Adenosine and stroke: maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant.

Authors:  Rebecca L Williams-Karnesky; Mary P Stenzel-Poore
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

8.  The adenosine A2A receptor antagonist ZM241385 enhances neuronal survival after oxygen-glucose deprivation in rat CA1 hippocampal slices.

Authors:  A M Pugliese; C Traini; S Cipriani; M Gianfriddo; T Mello; M G Giovannini; A Galli; F Pedata
Journal:  Br J Pharmacol       Date:  2009-05-05       Impact factor: 8.739

9.  Differential Expression of Adenosine P1 Receptor ADORA1 and ADORA2A Associated with Glioma Development and Tumor-Associated Epilepsy.

Authors:  Jun Huang; Ming-Na Chen; Juan Du; Hao Liu; Yu-Jiao He; Guo-Liang Li; Shu-Yu Li; Wei-Ping Liu; Xiao-Yan Long
Journal:  Neurochem Res       Date:  2016-04-02       Impact factor: 3.996

10.  HIF-1 alpha is an essential effector for purine nucleoside-mediated neuroprotection against hypoxia in PC12 cells and primary cerebellar granule neurons.

Authors:  Stephanie zur Nedden; Bettina Tomaselli; Gabriele Baier-Bitterlich
Journal:  J Neurochem       Date:  2008-02-04       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.